How genomics could help protect B.C.’s redcedars
Read More ❯
$140 million for UBC-led research hub to accelerate drug development and biomanufacturing
Read More ❯
New publication by UBC and Notch Therapeutics researchers aims to improve therapeutic design of living drugs
Read More ❯
New blood – UBC researchers develop process that could make blood types obsolete
Read More ❯
Biotechnology in BC: Future treatments and potential cures for cancer
Read More ❯
Adjunct professor Carl Hansen featured in media for successful AbCellera IPO
Read More ❯
How B.C. scientists are addressing the COVID-19 testing challenge
Read More ❯
Canada’s plan to mobilize science to fight COVID-19
Read More ❯
AbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-19
Read More ❯
Notch Therapeutics – a new company with a revolutionary allogeneic (“off the shelf”) T cell technology
Read More ❯
Pascal Biosciences and Y-Biologics Announce Research Collaboration for Development of a Bispecific Antibody for Leukemia
Read More ❯
AbCellera named one of Canada’s top growing companies
Read More ❯
Pascal Biosciences discovers cannabinoids activate the major histocompatibility complex to aid cancer treatment
Read More ❯
A transition to translation: Dr. Carl Hansen
Read More ❯
AbCellera wins 2019 Technology Impact Award for Company of the Year – Scale Success
Read More ❯
UBC cancer research supported by newly-developed partnership between Pascal Biosciences and Mitacs
Read More ❯
MSL research group spins-out an industry-leading biotechnology company
Read More ❯
AbCellera is growing!
Read More ❯
The BC Proteomics Network (BCPN): Collaboration and Research
Read More ❯
Microbiome Insights receives funding from the Government of Canada to develop new microbiome testing platform for managing chronic disease
Read More ❯
Tackling the world’s deadliest diseases one Ab at a time: an interview with Dr. Carl Hansen
Read More ❯
AbCellera is enabling the translation of laboratory research to clinical application for fibrosis associated with congenital degenerative diseases
Read More ❯
Vedanta Biosciences receives award from the Crohn’s & Colitis Foundation to advance a microbiome-derived therapeutic program
Read More ❯
Pascal Biosciences receives DEA Schedule I License for cannabinoid development and renews UBC collaboration
Read More ❯
Microbiome Insights expands to new lab facilities on UBC campus
Read More ❯
Renaissance BioScience Corp. partners with Mitacs for $1.44M project
Read More ❯
AbCellera awarded contract to develop a rapid response platform against pandemic viral threats
Read More ❯
Pascal Biosciences identifies molecules in cannabis that stimulate the immune system to destroy tumor cells
Read More ❯
Dr. Hieter and CSMB: ensuring a strong future for science and scientists
Read More ❯
Minister Ambrose announces new glycomics research network to prevent and treat diseases
Read More ❯